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1174Objectives: Stromal cell-derived factor (SDF)-1a is a potent endogenous endothelial progenitor cell (EPC)
chemokine and key angiogenic precursor. Recombinant SDF-1a has been demonstrated to improve neovasculo-
genesis and cardiac function after myocardial infarction (MI) but SDF-1a is a bulky protein with a short half-life.
Small peptide analogs might provide translational advantages, including ease of synthesis, low manufacturing
costs, and the potential to control delivery within tissues using engineered biomaterials. We hypothesized
that a minimized peptide analog of SDF-1a, designed by splicing the N-terminus (activation and binding)
and C-terminus (extracellular stabilization) with a truncated amino acid linker, would induce EPC migration
and preserve ventricular function after MI.
Methods: EPCmigration was first determined in vitro using a Boyden chamber assay. For in vivo analysis, male
rats (n¼ 48) underwent left anterior descending coronary artery ligation. At infarction, the rats were randomized
into 4 groups and received peri-infarct intramyocardial injections of saline, 3 mg/kg of SDF-1a, 3 mg/kg of
spliced SDF analog, or 6 mg/kg spliced SDF analog. After 4 weeks, the rats underwent closed chest pressure
volume conductance catheter analysis.
Results: EPCs showed significantly increased migration when placed in both a recombinant SDF-1a and spliced
SDF analog gradient. The rats treated with spliced SDF analog at MI demonstrated a significant dose-dependent
improvement in end-diastolic pressure, stroke volume, ejection fraction, cardiac output, and stroke work
compared with the control rats.
Conclusions: A spliced peptide analog of SDF-1a containing both the N- and C- termini of the native protein
induced EPC migration, improved ventricular function after acute MI, and provided translational advantages
compared with recombinant human SDF-1a. (J Thorac Cardiovasc Surg 2010;140:1174-80)After myocardial infarction (MI), microvascular dysfunc-
tion has been shown to be an important independent predic-
tor of ventricular remodeling, reinfarction, heart failure, and
death.1 Immediately after MI, the extent of microvascular
obstruction and infarct size increases significantly during
the first 48 hours and significant progressive microvascular
and myocardial injury occurs well beyond the infarct zone,
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The Journal of Thoracic and Cardiovascular Surincreased number of capillaries in these areas of ischemic
myocardium has been correlated with an increase in
contractility and function under stress conditions.4 The en-
dogenous machinery to repair injured and ischemic myocar-
dium is inadequate, and tremendous resources have been
devoted to developing molecular therapies that enhance
both the microvascular perfusion and the function of ische-
mic or infarcted myocardium. A significant portion of this
work has focused on angiogenic cytokines, including fibro-
blast growth factor, vascular endothelial growth factor, he-
patocyte growth factor, placental growth factor, and the
potent endothelial progenitor stem cell (EPC) chemokine
stromal cell-derived factor-1a (SDF-1a).
Experimentally, SDF-1a has been shown to be an effec-
tive angiogenic cytokine therapy. In an animal model of
chronic ischemic cardiomyopathy, peri-infarct myocardial
injection of SDF-1a caused significantly enhanced myocar-
dial EPC density, increased vasculogenesis, and augmented
myocardial function by enhancing perfusion, reversing
cellular ischemia, increasing cardiomyocyte viability, and
preserving the ventricular geometry.5,6
Despite promising preclinical results, SDF-1a has sev-
eral features that are not optimal for a widely translatablegery c November 2010
Abbreviations and Acronyms
DPBS ¼ Dulbecco’s phosphate-buffered saline
EPC ¼ endothelial progenitor cell
HPF ¼ high-power field
MI ¼ myocardial infarction
MNC ¼ marrow mononuclear cell
SDF ¼ stromal cell-derived factor
Hiesinger et al Evolving Technology/Basic Sciencetherapy. This large, 10-kD protein is quickly degraded by
proteases that are activated at sites of injury, including
dipeptidyl peptidase IV and matrix metalloproteinase-2.7,8
In addition, the delivery of SDF-1a would be further
complicated by the high manufacturing costs and rapid
diffusion of the chemokine away from the targeted site.9
We believe that small peptide analogs, functionally compa-
rable to native SDF-1a, could provide translational advan-
tages, including ease of synthesis, low manufacturing
costs, and the potential to control delivery within tissues us-
ing engineered biomaterials.
Previous studies have demonstrated that a minimized
peptide analog of SDF-1a, designed by deleting the large
central b-sheet region and splicing the N-terminus (activa-
tion and binding site) and C-terminus (extracellular stabili-
zation region) with a truncated amino acid linker consisting
of 4 glycines, would induce in vitro intracellular calcium
release and T1 cell migration (Figure 1).10 In the present
study, we hypothesized that this small, spliced SDF-1a
analog would induce EPC migration and preserve ventricu-
lar function after MI in a similar fashion to native SDF-1a.
In doing so, this truncated peptide analog would provide
a novel foundation for the clinical translation of cytokine-
based neovasculogenic therapy, as well as a logical jumping
off point for the rational design and re-engineering of the
SDF-1a peptide to enhance stability and in vivo function.FIGURE 1. Depiction of N- and C-termini of stromal cell-derived facto
The Journal of Thoracic and CarMATERIALS AND METHODS
Peptide Synthesis
The spliced SDF-1a analog peptide was synthesized using solid phase
peptide synthesis (AnaSpec, San Jose, Calif), which involves the incorpo-
ration of N-a-amino acids into a peptide of any desired sequence with one
end of the sequence remaining attached to a solid support matrix. After the
desired sequence of amino acids has been obtained, the peptide is removed
from the polymeric support.
Cell Isolation
Bone marrow mononuclear cells (MNCs) were isolated from the long
bones of adult male green fluorescent protein-Wistar rats using density-
gradient centrifugation with Histopaque 1083 (Sigma Chemical, St. Louis,
Mo) and cultured in endothelial basal medium-2 supplemented with EGM-
2 Singlequot (Lonza, Basel, Switzerland) containing human epidermal
growth factor, fetal bovine serum, vascular endothelial growth factor, hu-
man fibroblast growth factor-B, R3-insulin-like growth factor-1, ascorbic
acid, heparin, gentamicin, and amphotericin-B. The combination of
endothelial-specific media and the removal of nonadherent MNCs was in-
tended to select for the EPC phenotype.
Functional Characterization of Isolated EPCs Using
Boyden Chamber Assay
Thewidely usedBoyden chamber assay (Neuro Probe, Inc, Gaithersburg,
Md)was used to assess EPCmigration.11-13 In brief, 8-mmfilterswere loaded
into control and experimental chambers. The 14-day EPCs, cultured in
endothelial-specific media on vitronectin-coated plates, were trypsinized,
counted, and brought to a concentration of 90 cells/mL in Dulbecco’s
phosphate-buffered saline (DPBS). The bottom chamber of the control and
experimental chambers were loaded with DPBS, 50 ng/mL recombinant
SDF (R&D Systems, Minneapolis, Minn) in DPBS, 50 ng/mL of the spliced
SDF analog in DPBS, or 100 ng/mL of the spliced SDF analog in DPBS. A
560-mLcell suspensionwas added to the topchamber of each.All 3 chambers
were incubated at 37C in 5% carbon dioxide for 4 hours. The cells remain-
ing in the top chamberwerewiped cleanwith a cotton swab, and thefilterwas
removed. The slides were visualized on a DF5000B Leica Fluorescent scope
and analyzed using LASAF, version 2.0.2, software (Leica Microsystems,
Wetzlar, Germany). Boyden chamber analysis was performed in triplicate.
Animal Care and Biosafety
Male Lewis rats weighing 250 to 300 g were obtained from Charles
River Laboratories International Inc (Wilmington, Mass). Food and waterr (SDF) linked by 4 glycines (A), with and (B) without side chains.
diovascular Surgery c Volume 140, Number 5 1175
E
T
/B
S
Evolving Technology/Basic Science Hiesinger et al
E
T
/B
Swere provided ad lib. This investigation conformed to the Guide for the
Care and Use of Laboratory Animals published by the US National Insti-
tutes of Health (Publication No. 85-23, revised 1996) and was approved
by the Institutional Animal Use and Care Committee of the University of
Pennsylvania (protocol no. 802076).
Ischemic Cardiomyopathy Model
The rats were anesthetized with ketamine (75 mg/kg) and xylazine
(7.5 mg/kg), intubated with a 16-gauge catheter, and mechanically
ventilated (Hallowell EMC, Hallowell Engineering and Manufacturing
Corp, Pittsfield, Mass) with tidal volume (Vt) (mL) ¼ 6.2 3 M1.01 (where
M is the animal mass in kilograms) and respiratory rate
(min1)¼ 53.53M0.26.14 A thoracotomy was performed in the left fourth
intercostal space, and a 7-0 polypropylene suturewas placed around themid-
left anterior descending coronary artery 2 mm inferior to the left atrial ap-
pendage and ligated to produce a large anterolateral MI of 30% of the left
ventricle. The extent of infarction was highly reproducible, and progression
to cardiomyopathyhas beenwell documented.5,6,15-17 Immediately afterMI,
the rats were randomized into 4 groups and received peri-infarct intramyo-
cardial injections of saline (n¼ 12), SDF-1a (3 mg/kg, n¼ 12), spliced SDF
analog at 3 mg/kg (n¼ 12), or spliced SDF analog at 6 mg/kg (n¼ 12). The
rats were injected using a 30-gauge needle into 5 predetermined regions in
theperi-infarct border zone, definedas 1microscopicfield lateral to themyo-
cardial scar.18 The thoracotomywas then closed, and the ratswere implanted
with identification microchips (BioMedic Data Systems Inc, Boise, Idaho)
and recovered. Buprenorphine (0.5 mg/kg) was administered for postopera-
tive analgesia. Identification data were maintained by an investigator who
did not participate in the subsequent data collection or analysis. All 3 exper-
imental treatment groups received subcutaneous injections of 40 mg/kg
liquid sargramostim (granulocyte-macrophage colony-stimulating factor),
diluted in saline, for a total volume of 200 mL immediately postoperatively
and on postoperative day 1. An additional control group (n ¼ 12) also
received subcutaneous injections of 40 mg/kg of granulocyte-macrophage
colony-stimulating factor immediately postoperatively and on postoperative
day 1, in addition to peri-infarct intramyocardial injections of saline.FIGURE 2. Using Boyden chamber assay, isolated endothelial progenitor cells
analog gradients. Images are representative of Boyden chamber filters from eac
SDF Analog (23) image.
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At 4 weeks after left anterior descending coronary artery ligation, the
control and experimental rats (control group, n ¼ 12; SDF-1a at 3 mg/
kg, n¼ 12; spliced SDF analog at 3 mg/kg, n¼ 12; and spliced SDF analog
at 6 mg/kg, n ¼ 12) underwent invasive hemodynamic measurements with
a pressure-volume conductance catheter (SPR-869, Millar Instruments Inc,
Houston, Tex). The catheter was calibrated using 5-point cuvette linear in-
terpolation with parallel conductance subtraction by the hypertonic saline
method.14 The rats were anesthetized, and the catheter was introduced into
the left ventricle with a closed-chest approach by way of the right carotid
artery. Measurements were obtained before and during inferior vena cava
occlusion to produce static and dynamic pressure-volume loops under
varying load conditions. The data were recorded and analyzed using Lab-
Chart, version 6, software (ADInstruments, Colorado Springs, Colo) and
ARIA pressure volume analysis software (Millar Instruments).
Statistical Analysis
The unpaired Student t test was used to compare the groups. Values are
expressed as the mean  standard error of the mean.RESULTS
EPCs Cultured in Endothelial-Specific Media
Exhibited Enhanced Migration When Exposed to
Spliced SDF Analog Gradient
Using a Boyden chamber assay, the 14-day endothelial
progenitor cells showed significantly increased migration
when placed in both a recombinant human SDF-1a and
spliced SDF analog gradient (control group, 47  9 cells/
high-power field [HPF] vs SDF-1a, 240  20 cells/HPF,
P ¼ .009; control vs spliced SDF analog, 237  11 cells/
HPF, P< .001; and control vs spliced SDF analog [23],
461  28 cells/HPF, P ¼ .004; Figure 2). In addition, we(EPCs) showed increased migration when placed in SDF and spliced SDF
h group. Green fluorescent protein–positive cells were used in the Spliced
gery c November 2010
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that significantly more cells migrated in the [23] spliced
SDF analog gradient than in either the SDF-1a or [13]
spliced SDF analog gradient (P<.01 for both).
Invasive Hemodynamic Assessment Showed Dose-
Dependent Improvement in Left Ventricular
Function After Spliced SDFAnalog Treatment
The rats treated with recombinant human SDF-1a and
spliced SDF analog (both 3 and 6 mg/kg doses) exhibited
statistically significant preservation of cardiac function
compared with the control rats (Figure 3). The rats treated
with the high-dose spliced SDF analog demonstrated a sig-FIGURE 3. Representative pressure-volume loops from all 4 experimental
cell-derived factor (SDF) and spliced SDF analog-treated groups compared wit
The Journal of Thoracic and Carnificant dose-dependent improvement in stroke volume,
ejection fraction, cardiac output, and arterial elastance com-
pared with the low-dose spliced SDF analog group. The
high-dose splicedSDFanaloggroup alsodemonstrated a sig-
nificant improvement in ejection fraction and cardiac output
compared with the recombinant human SDF-1a (3mg/kg)
group (Table 1). The saline control group that received sub-
cutaneous injections of granulocyte-macrophage colony-
stimulating factor was significantly inferior or equivalent
to the saline-only control group for all parameters assessed
(end diastolic pressure, 14.4mmHg,P¼ .17; stroke volume
157.9 mL, P¼ .05; ejection fraction, 21.6%, P¼ 0.11; car-
diac output, 33,865.8 mL/min, P ¼ .09; stroke work,groups depicting greater ejection fraction and cardiac output in stromal
h the control group.
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TABLE 1. Invasive hemodynamic assessment showing dose-dependent improvement in left ventricular function after spliced SDF analog
treatment
Invasive hemodynamic assessment Control group (n ¼ 12) rhSDF-1a (n ¼ 12)
Spliced SDF peptide analog
3 mg/kg (n ¼ 12) 6 mg/kg (n ¼ 12)
End-diastolic pressure (mm Hg) 18.5  2 25.0  2.5 23.4  2 24.3  2.5
P value
Versus control group .03 .05 .04
Versus rhSDF group .31 .43
Versus peptide 3 mg/kg .39
Stroke volume (mL) 188.8  14.5 261.2  19.7 244.2  20.2 290.4  10.6
P value
Versus control group .04 .019 .001
Versus rhSDF group .28 .10
Versus peptide 3 mg/kg .03
Ejection fraction (%) 24.37  1.7 32.7  2 30.57  1.9 36.93  1
P value
Versus control group .02 .013 .001
Versus rhSDF group .22 .04
Versus peptide 3 mg/kg .005
Cardiac output (mL/min) 39,270  2927 52,184  3532 50,670  4086 60,764  2297
P value
Versus control group .05 .017 .001
Versus rhSDF group .39 .03
Versus peptide 3 mg/kg .02
Stroke work (mm Hg/mL) 11,789  1079 17,180  1501 16,623  1498 19,736  1147
P value
Versus control group .04 .08 .001
Versus rhSDF group .40 .095
Versus peptide 3 mg/kg .06
Arterial elastance (mm Hg/mL) 0.56  0.05 0.39  0.04 0.45  0.05 0.32  0.02
P value
Versus control group .07 .07 .001
Versus rhSDF group .14 .07
Versus peptide 3 mg/kg .008
rhSDF, Recombinant human stromal cell-derived factor.
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mm Hg/mL, P ¼ .12).
DISCUSSION
Therapeutic angiogenesis is a clearly safe and feasible
therapy for ischemic heart disease. However, despite a myr-
iad of favorable experimental results, the body of clinical
data is large and lacks a clear consensus. Several questions
need to be answered before angiogenic cytokines can
become a widely used and efficacious treatment. An ideal
agent needs to be identified, followed by the ideal form of
said angiogenic cytokine, and, finally, the optimal dose
needs to be determined.19
We believe that SDF-1a, the most potent and specific
angiogenic cytokine, is an ideal choice. Stromal cell–
derived factor-1a, is a 68-amino acid peptide belonging to
the CXC family of chemokines and is the sole ligand for
the G protein-coupled receptor, CXCR4, through which its
biologic effects are mediated. SDF-1a is a key regulator1178 The Journal of Thoracic and Cardiovascular Surof physiologic cell motility both during embryogenesis
and after birth and is constitutively expressed in a wide
variety of cells, including endothelial cells, dendritic cells,
and stromal cells.20 This powerful chemoattractant is
significantly upregulated in response to both myocardial is-
chemia and infarction and has been shown to effect EPC
proliferation and mobilization to induce vasculogene-
sis.21,22 Its sole target, the CXCR4 cell-surface antigen, is
expressed in significant levels on CD34þ EPCs, and the
expression of this receptor is related to efficient SDF-
induced transendothelial migration.23 In addition, SDF has
repeatedly been shown to play a critical role in the rescue
ofmyocardial function and stem cell recruitment to the heart
after MI.24-27 However, we do not believe that recombinant
human SDF is the ideal form of this angiogenic cytokine
for widespread translation. Small peptide analogs,
functionally comparable to native SDF-1a, might provide
translational advantages, including ease of synthesis, low
manufacturing costs, and the potential to control deliverygery c November 2010
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study, we have demonstrated that a minimized peptide
analog of SDF that spliced the receptor binding
N-terminus and the extracellular stabilizing C-terminus
with a 4-glycine amino acid chain could induce EPC
migration and preserve ventricular function after MI in
a similar fashion to SDF.
SDF cytokine therapy mobilizes marrow-based EPCs
to form new microvasculature and perfuse ischemic
myocardium. Using a Boyden chamber assay, we showed
that endothelial progenitor cells exhibited significantly in-
creased migration when placed in both a recombinant
human SDF and a spliced SDF analog gradient. A dose-
response effect was also apparent. This assay revealed
that, despite the deletion of the large central b-sheet region,
the spliced SDF analog retains the chemotactic homing
mechanism of native SDF critical to myocardial EPC
recruitment and vessel formation.
Endogenous revascularization for ischemic cardiomyop-
athy using SDF-mediated EPC chemokinesis enhances cir-
culating EPC density and augments myocardial function
by enhancing perfusion, reversing cellular ischemia, and
increasing cardiomyocyte viability.5 It would follow logi-
cally that the spliced SDF analog would similarly be able
to rescue myocardial function in the setting of acute ische-
mic insult if it retained a significant proportion of native
SDF activity. The rats treated with recombinant human
SDF and spliced SDF analog (both 3- and 6-mg/kg doses)
exhibited statistically significant preservation of cardiac
function compared with the control group. Also, the high-
dose spliced SDF analog group demonstrated a significant
improvement in the ejection fraction and cardiac output
compared with the recombinant human SDF group. This
in vivo evidence has demonstrated once again that the
spliced SDF analog retains critical native SDF activity
despite its truncated polypeptide sequence.
Experimentally, treatment with SDF has been effective at
multiple different points. It has been delivered at the time of
MI, such as was done in the present study, and up to 3 weeks
after MI. We believe this microrevascularization strategy
can serve as a primary therapy at any point in the disease
process and can be used synergistically with traditional cor-
onary revascularization methods. Small peptide analogs
of SDF incorporated into sustained release vesicles could
be delivered into the coronary circulation during any
catheter-based intervention to augment collateralization.
They could also be deployed during open cardiac proce-
dures, either as a direct injection into areas of ischemic
myocardium without graft-able target vessels or incorpo-
rated into an engineered biomaterial overlay. Additionally,
SDF has been used to ‘‘supercharge’’ stem cell therapy.28
The potential clinical applications for SDF-based angio-
genic therapy are limited only by the imagination and
the restrictions imposed by the SDF molecule itself. TheThe Journal of Thoracic and Carpresent study represents the first foray into the design and
construction of a maximally efficient, translatable SDF
molecule analog.
CONCLUSIONS
A spliced peptide analog of SDF-1a containing both the
N- and C- termini of the native protein induced EPC migra-
tion, improved ventricular function after acute MI, and
provided a novel foundation for the clinical translation of
cytokine-based neovasculogenic therapy. The purpose of
the present study was not to recapitulate all the previous
SDF-based experiments, but rather to serve as a proof of
concept that a synthetic, minimized SDF peptide can retain
the functional properties of native SDF, despite major con-
formational changes. From this initial success, future inves-
tigations will attempt to further refine the ‘‘ideal form’’ of
a widely translatable SDF peptide using advanced computa-
tional techniques.
References
1. Bolognese L, Carrabba N, Parodi G, Santoro GM, Buonamici P, Cerisano G, et al.
Impact of microvascular dysfunction on left ventricular remodeling and long-
term clinical outcome after primary coronary angioplasty for acute myocardial
infarction. Circulation. 2004;109:1121-6.
2. Rochitte CE, Lima JA, Bluemke DA, Reeder SB, McVeigh ER, Furuta T, et al.
Magnitude and time course of microvascular obstruction and tissue injury after
acute myocardial infarction. Circulation. 1998;98:1006-14.
3. Tarantini G, Razzolini R, Cacciavillani L, Bilato C, Sarais C, Corbetti F, et al.
Influence of transmurality, infarct size, and severe microvascular obstruction
on left ventricular remodeling and function after primary coronary angioplasty.
Am J Cardiol. 2006;98:1033-40.
4. Heilmann C, Kostic C, Giannone B, Grawitz AB, Armbruster W, Lutter G,
et al. Improvement of contractility accompanies angiogenesis rather than arte-
riogenesis in chronic myocardial ischemia. Vascul Pharmacol. 2006;44:
326-32.
5. Atluri P, Liao GP, Panlilio CM, Hsu VM, Leskowitz MJ, Morine KJ, et al. Neo-
vasculogenic therapy to augment perfusion and preserve viability in ischemic
cardiomyopathy. Ann Thorac Surg. 2006;81:1728-36.
6. Woo YJ, Grand TJ, Berry MF, Atluri P, Moise MA, Hsu VM, et al. Stromal cell-
derived factor and granulocyte-monocyte colony-stimulating factor form a
combined neovasculogenic therapy for ischemic cardiomyopathy. J Thorac
Cardiovasc Surg. 2005;130:321-9.
7. McQuibban GA, Butler GS, Gong JH, Bendall L, Power C, Clark-Lewis I, et al.
Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-
derived factor-1. J Biol Chem. 2001;276:43503-8.
8. Segers VF, Tokunou T, Higgins LJ, MacGillivray C, Gannon J, Lee RT.
Local delivery of protease-resistant stromal cell derived factor-1 for stem
cell recruitment after myocardial infarction. Circulation. 2007;116:
1683-92.
9. He X,Ma J, Jabbari E.Migration of marrow stromal cells in response to sustained
release of stromal-derived factor-1alpha from poly(lactide ethylene oxide fuma-
rate) hydrogels. Int J Pharm. 2010;390:107-16.
10. Luo J, Luo Z, Zhou N, Hall JW, Huang Z. Attachment of C-terminus of SDF-1
enhances the biological activity of its N-terminal peptide. Biochem Biophys
Res Commun. 1999;264:42-7.
11. Bonaros N, Sondermeijer H, Schuster M, Rauf R, Wang SF, Seki T, et al. CCR3-
and CXCR4-mediated interactions regulate migration of CD34þ human bone
marrow progenitors to ischemic myocardium and subsequent tissue repair.
J Thorac Cardiovasc Surg. 2008;136:1044-53.
12. Ruel M, Suuronen EJ, Song J, Kapila V, Gunning D, Waghray G, et al. Effects of
off-pump versus on-pump coronary artery bypass grafting on function and viabil-
ity of circulating endothelial progenitor cells. J Thorac Cardiovasc Surg. 2005;
130:633-9.
13. Zhang Y, Wong S, Lafleche J, Crowe S, Mesana TG, Suuronen EJ, et al. In vitro
functional comparison of therapeutically relevant human vasculogenicdiovascular Surgery c Volume 140, Number 5 1179
Evolving Technology/Basic Science Hiesinger et al
E
T
/B
Sprogenitor cells used for cardiac cell therapy. J Thorac Cardiovasc Surg. 2010;
140:216-24. 24e1-4.
14. Pacher P, Nagayama T, Mukhopadhyay P, Batkai S, Kass DA. Measurement of
cardiac function using pressure-volume conductance catheter technique in
mice and rats. Nat Protoc. 2008;3:1422-34.
15. Woo YJ, Panlilio CM, Cheng RK, Liao GP, Atluri P, Hsu VM, et al. Therapeutic
delivery of cyclin A2 induces myocardial regeneration and enhances cardiac
function in ischemic heart failure. Circulation. 2006;114(1 Suppl):I206-13.
16. Woo YJ, Panlilio CM, Cheng RK, Liao GP, Suarez EE, Atluri P, et al. Myocardial
regeneration therapy for ischemic cardiomyopathy with cyclin A2. J Thorac Car-
diovasc Surg. 2007;133:927-33.
17. Liu YH, Yang XP, Nass O, Sabbah HN, Peterson E, Carretero OA. Chronic heart
failure induced by coronary artery ligation in Lewis inbred rats. Am J Physiol.
1997;272(2 Pt 2):H722-7.
18. Jayasankar V, Bish LT, Pirolli TJ, Berry MF, Burdick J, Woo YJ. Local myocar-
dial overexpression of growth hormone attenuates postinfarction remodeling and
preserves cardiac function. Ann Thorac Surg. 2004;77:2122-9.
19. Renault MA, Losordo DW. Therapeutic myocardial angiogenesis. Microvasc
Res. 2007;74:159-71.
20. De La Luz SierraM, Yang F, NarazakiM, Salvucci O, Davis D, Yarchoan R, et al.
Differential processing of stromal-derived factor-1alpha and stromal-derived fac-
tor-1beta explains functional diversity. Blood. 2004;103:2452-9.
21. Pillarisetti K, Gupta SK. Cloning and relative expression analysis of rat stromal
cell derived factor-1 (SDF-1)1: SDF-1 alpha mRNA is selectively induced in rat
model of myocardial infarction. Inflammation. 2001;25:293-300.1180 The Journal of Thoracic and Cardiovascular Sur22. Yamaguchi J, Kusano KF, Masuo O, Kawamoto A, Silver M, Murasawa S, et al.
Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor
cell recruitment for ischemic neovascularization. Circulation. 2003;107:1322-8.
23. Mohle R, Bautz F, Rafii S, Moore MA, Brugger W, Kanz L. The chemokine re-
ceptor CXCR-4 is expressed on CD34þhematopoietic progenitors and leukemic
cells and mediates transendothelial migration induced by stromal cell-derived
factor-1. Blood. 1998;91:4523-30.
24. Abbott JD, Huang Y, Liu D, Hickey R, Krause DS, Giordano FJ. Stromal cell-
derived factor-1alpha plays a critical role in stem cell recruitment to the heart af-
ter myocardial infarction but is not sufficient to induce homing in the absence of
injury. Circulation. 2004;110:3300-5.
25. Askari AT, Unzek S, Popovic ZB, Goldman CK, Forudi F, Kiedrowski M, et al.
Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regenera-
tion in ischaemic cardiomyopathy. Lancet. 2003;362:697-703.
26. Tang J, Wang J, Yang J, Kong X, Zheng F, Guo L, et al. Mesenchymal stem cells
over-expressing SDF-1 promote angiogenesis and improve heart function in exper-
imental myocardial infarction in rats. Eur J Cardiothorac Surg. 2009;36:644-50.
27. Zhao T, Zhang D, Millard RW, Ashraf M, Wang Y. Stem cell homing and angio-
myogenesis in transplanted hearts are enhanced by combined intramyocardial
SDF-1alpha delivery and endogenous cytokine signaling. Am J Physiol Heart
Circ Physiol. 2009;296:H976-86.
28. Frederick JR, Fitzpatrick JR, McCormick RC, Harris DA, Kim AY, Muenzer JR,
et al. Stromal cell-derived factor-1a activation of tissue engineered endothelial
progenitor cell matrix enhances ventricular function after myocardial infarction
by inducing neovasculogenesis. Circulation. In press.gery c November 2010
